Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Public Health 104, 512519
Hard-won progress can quietly slip away without a plan
Tirzepatide GLP-1)It is a GLP-1 receptor agonist with multiple effects
GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Compounded semaglutide varies and lacks consistent dosing information
Its dosing frequency of monthly or less frequent injections represents a potential patient experience advantage over Ozempic's weekly injection if Phase 3 data confirm Phase 2 results
US$ 20.12
US$ 25.98
US$ 22.40
US$ 21.02
